ICOS
Inducible T-cell costimulator
As of the edition of 20 October 2026, ICOS (inducible T-cell costimulator, UniProt Q9Y6W8) has 7 drugs tested at it and 7 companies on the list, 6 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y6W8
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Solved structures
- 2
- Disease areas
- Cancer; Immune system; Skin and connective tissue; Lungs and airways; Blood and lymph; Pregnancy and women's health; Urinary and reproductive; Digestive system
- Registered trials of its drugs
- 25
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Stopped | 5 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Feladilimab | Stopped | Phase 3 | none listed |
| Vopratelimab | Stopped | Phase 2 | none listed |
| Izuralimab | Stopped | Phase 2 | none listed |
| Rozibafusp alfa | Active | Phase 2 | none listed |
| Acazicolcept | Stopped | Phase 2 | none listed |
| MEDI-570 | Went quiet | Phase 1 | none listed |
| Alomfilimab | Stopped | Phase 2 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Engaged | 1 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| GSK | Route A |
| AstraZeneca | Route A |
| Xencor | Route A |
The other 4 companies at ICOS
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at ICOS, ranked, with the facts behind eachRequest access. Nothing is shown until you do.